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Abstract 
Elucidation of the structure-function relationship of membrane proteins increases our 
understanding of many biological processes, both physiological and pathological. 
However, membrane proteins have been notoriously difficult to study, having part of their 
structure embedded into the lipid cell membrane. The work presented herein describes 
related functional and structural studies of the human ion channel TRPV1 as well as 
method development for studies on membrane proteins. First, the effect of membrane 
cholesterol levels on TRPV1 function was evaluated with patch-clamp recordings and 
cholesterol-depletion inhibited a time-dependent increase in permeability of large cations. 
Secondly, a microfluidic flow cell was developed for proteomic studies of membrane 
proteins where proteoliposomes derived from cell membranes were immobilized and 
constituted a stationary phase of membrane proteins. In addition, a sequential digestion 
protocol for limited proteolysis within the flow cell was developed for proteomic 
profiling and digested peptides were identified with mass spectrometry. Moreover, 
limited proteolysis was performed on TRPV1 for evaluation of surface exposed regions. 
Identical digestions were performed during inside-out patch-clamp experiments in order 
to correlate TRPV1 structure with function. Removal of intracellular peptide regions 
decreased ion channel activity. Finally, the flow cell was employed for generation of 
antibody epitopes suitable for development of therapeutic antibodies. Two antibodies 
were raised against intracellular domains of TRPV1 and were further evaluated for their 
effect on TRPV1 activity using patch-clamp and fluorescence studies. Both antibodies 
altered TRPV1 activity. This methodology may thus constitute an effective strategy for 
generation of therapeutic antibodies. 
Keywords: Membrane proteins, ion channels, antibodies, TRPV1, patch clamp, 
fluorescence, limited proteolysis, proteomics, mass spectrometry, cholesterol. 
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1
INTRODUCTION
The molecular actions of proteins are fundamental to all forms of life. While the genetic 
code provides a blueprint for each living organism it is the proteins that execute these
instructions, e.g. by catalyzing reactions, transmitting signals, transporting molecules,
providing defense mechanisms, creating movement and providing structural integrity.
Roughly 20–30% of all human genes encodes for membrane proteins [1], [2]. These are 
proteins performing their functions while being associated with cellular membranes. 
More than 60% of all drug targets are membrane proteins due to their unique abilities to 
convey signals from the extracellular milieu to the cell interior [3], [4]. Dysfunctional 
membrane proteins are implicated in many severe diseases, e.g. cystic fibrosis [5],
Alzheimer's disease [6], several cancers [7]–[9] as well as in psychiatric diseases such as 
schizophrenia, major depression  and bipolar disorder [10], [11]. Detailed data that 
describes protein–protein interactions, conformation dynamics, ligand–protein
interactions and posttranslational modifications, that is, information that couples structure 
to function of these proteins, may aid the discovery of new pharmaceuticals for improved 
treatment of many diseases. However, the development of novel drugs targeting 
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membrane proteins is greatly hampered by the lack of structural knowledge. As of mid 
2015, the protein data bank [12], [13] contains over 100 000 structural entries while less 
than 3% are classified as belonging to membrane proteins. The reason for this 
discrepancy is mainly due to low abundance of membrane proteins compared to cytosolic 
proteins and their inherent structure with hydrophobic regions spanning the cell 
membrane, which complicates the use of traditional structural biology techniques such as 
NMR spectroscopy and X-ray crystallography [14], [15]. Many analytical methods 
require proteins to be freely dissolved in aqueous solutions. Such conditions will, 
however, cause extracted membrane proteins to aggregate and precipitate. Detergents, 
salts and organic solvents are commonly used to maintain membrane protein 
solubility [16], but it is a delicate balance to keep these hydrophobic proteins in solution 
while at the same time limit disruption of their function and native structure. Protocols for 
enrichment of membrane proteins, their extraction from the membrane and subsequent 
solubilization need to be developed and optimized on a case to case basis.  
The importance of this protein class and the demand for functional and structural data has 
driven the development of novel techniques for membrane protein studies that 
complement traditional techniques. Large scale proteomic studies have been facilitated by 
the evolvement of mass spectrometry based techniques [17]–[21]. Mass spectrometry 
requires less material and can handle complex mixtures of proteins, and provides detailed 
analysis of purified proteins. The technique has e.g. been utilized to study the interaction 
of membrane protein complexes by embedding the complex into detergent micelles prior 
to mass spectrometry analysis. The detergents are subsequently removed upon collision 
activation, enabling detection of individual subunits [22], [23]. 
The work described in this thesis has aimed to increase the knowledge of membrane 
protein structure and function. It includes both functional and structural studies of the 
human transient receptor potential vanilloid 1 (TRPV1) nociceptive ion channel and the 
development of methods that were validated using TRPV1 as a model membrane protein. 
A microfluidic cell was developed where membrane proteins can reside in their native 
membrane while they are exposed to different chemical treatments. This flow cell was 
used in combination with mass spectrometry to probe surface topology of the TRPV1 ion 
channel. The function of these regions were subsequently evaluated using patch-clamp 
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recording, an electrophysiological technique which is the gold standard for functional 
studies of ion channels [24]. Patch-clamp recording was also used to study how the 
cholesterol content of the cell membrane affects the activity of TRPV1. Ion channel 
activity was found to be dependent on cholesterol content. This information increases our 
knowledge about pain reception but also highlights the need for a correct lipid 
composition during membrane protein studies and the benefits of using native membranes 
in the microfluidic flow cell. Finally, the flow cell was utilized to detect surface exposed 
regions of TRPV1 which were thereafter used for the development of two antibodies 
targeting the intracellular side of TRPV1. Both of these antibodies were shown to have 
the ability to alter TRPV1 response. Antibodies are the fastest growing class of 
therapeutic drugs [25] due to their ability to bind a drug target (e.g. a membrane protein) 
with great specificity. Utilizing the microfluidic flow cell to pin-point regions on a 
membrane protein that can be targeted by an antibody is a completely novel tool which 
has the potential to greatly aid current techniques for antibody development. 
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2
MEMBRANE PROTEINS
The cell membrane defines the boundary of a living cell. It acts as a protective barrier, 
separating the interior of the cell from the extracellular environment while at the same 
time maintaining the cells’ structural integrity. It is comprised of lipids arranged into a 
bilayer and can be described as a dynamic, thin fluid film. While this structure is provided 
by the self-assembly of lipid molecules many of its biological functions, such as transport 
and signaling, are performed by membrane proteins. These are proteins embedded in, or 
associated with the lipid bilayer and generally constitute 50% of the total membrane mass 
[26]. Membrane proteins perform a vast variety of essential functions such as mediating
communication between cells, transferring signals between the exterior and interior of the 
cell, cellular respiration, transport of ions across the cell membrane, and promoting 
adhesion of cells to form larger tissues [26]
 
.
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2.1 The cell membrane
The main lipid components of the cell membrane are phospholipids, glycolipids and 
sterols. Phospholipids, the most abundant lipids in the cell membrane, are amphiphilic 
molecules, consisting of a hydrophilic head group, a glycerol linker, and hydrophobic 
fatty acid chains. When placed in aqueous solutions, phospholipids will spontaneously 
arrange themselves into a lipid bilayer (Figure 2.1). The hydrophilic part will face the 
aqueous surroundings and the hydrophobic parts will be located in the interior of the 
bilayer, shielded from water [27].
Figure 2.1 A phospholipid is constructed of a hydrophilic headgroup and two hydrophobic 
hydrocarbon chains (top). Several of these phospholipids will spontaneosly arrange themselves 
into a spherical bilayer, a liposome, in aqueous solutions (middle). A liposome can be viewed as a
simplified comparison of a cell membrane. A biological cell membrane is functionalized with a 
large amount of membrane proteins (bottom) and contain different lipid molecules.
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The lipid bilayer is impermeable to charged molecules and large polar compounds since 
their passive diffusion is inhibited by the hydrophobic interior of the bilayer. Sterols, such 
as cholesterol in mammalian cell membranes, increase the packing order of phospholipids 
within the membrane, which provides mechanical strength and further decreases its 
permeability [28]. This is an important property of the cell membrane, since an exactly 
defined ionic composition of the intracellular milieu is crucial for many biological 
processes. Additional, internal membranes provide further compartmentalization of the 
cell into different organelles, which enables local environmental differences optimized for 
various types of biochemical reactions [27]. 
2.2 Membrane protein structure 
Membrane proteins can interact with the cell membrane in several ways. Integral proteins 
or transmembrane proteins are amphiphilic proteins that have one or several membrane 
spanning segments as well as regions that are exposed to the aqueous environment on 
either side of the membrane (Figure 2.2). The amino acid sequences located within the 
bilayer commonly have hydrophobic side chains in order to be soluble in the hydrophobic 
membrane core. The peptide bonds are, however, polar and are kept shielded through the 
formation of secondary structures such as α-helices and β-barrels [29]. Membrane 
proteins consisting of a β-barrel have alternating hydrophobic and hydrophilic amino 
acids where the hydrophobic amino acids are facing the lipid bilayer, and the hydrophilic 
amino acids are facing the interior of the barrel. This creates an hydrophilic cavity which 
can be used to transport water soluble molecules through the membrane [29]. An example 
of such a protein class is the porins. Membrane proteins consisting of α-helices typically 
have one or more α-helices spanning the membrane. Several α-helices are connected with 
loops that extend on either side of the membrane. The N- and C-termini can be located on 
both the same or opposite sides of the membrane [27], [29]. A class of membrane proteins 
that is constituted out of α-helices is G protein-coupled receptors (GPCRs) that have 7 
transmembrane α-helices with the purpose of conveying signals from the cell exterior to 
the interior. 
Peripheral membrane proteins or membrane-associated proteins are proteins that function 
solely on one side of the cell membrane and have a majority of their structure in a 
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hydrophilic environment. Peripheral membrane proteins may be linked to the membrane 
by insertion of a hydrophobic region into the lipid bilayer, by covalent attachment of an 
amino acid to a lipid or by binding to another membrane protein [27], [30].
Figure 2.2 Examples of different structural arrangements of transmembrane proteins. Proteins 
having either one (left) or several (midd le) α-helices spanning the cell membrane are the largest 
class of transmembrane proteins .  Proteins  consisting  of  a  β-barrel spanning the membrane (right) 
are less common but comparatively easier to dissolve and study.
2.3 Ion channels
Ion channels have different functions in the human body, e.g. in signal transduction 
processes leading to the generation of electrical impulses along nerves in the central and 
peripheral nervous system, the heart and other organs. 
The basis of this signal transduction, involving ion channels, is that living cells have a
different ionic composition in the cytosol compared to the extracellular environment 
(Table 2.1), which gives rise to an electrical potential across the cell membrane, defined 
as the membrane potential [31]. The K+ concentration is normally higher in the cytosol,
and the Na+ concentration is higher on the extracellular side. This electrochemical 
gradient is maintained through the activity of membrane proteins, actively or passively 
transporting ions across the membrane. Two main classes of transmembrane proteins, ion 
pumps and ion channels, are responsible for this process. Ion pumps transport ions against 
their concentration gradient using energy. For example, the sodium-potassium pump 
hydrolyzes ATP to transport three Na+-ions out of the cell while at the same time 
transporting two K+ -ions inside the cell. Thus, it establishes and maintains the difference 
in K+/ Na+ concentrations. While transport of ions using ion pumps is a slow process, ion
channels are pore forming proteins that open or close upon stimuli (Figure 2.3) and allow 
specific ions to rapidly diffuse down their concentration gradient [32]. Rapid transfer of 
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ions along their concentration gradient will cause a change in membrane potential, a 
mechanism that is crucial for many biological processes e.g. nerve signaling. During 
nerve signaling, a local depolarization of the membrane triggers the opening of Na+-
channels, causing an influx of Na+-ions, which in turn further depolarize the membrane. 
This causes neighboring Na+-channels to open and the nerve signal, an action potential, 
will propagate along the nerve cell. The opening of Na+-channels is followed by a 
refractory period in which these channels are inactivated. The refractory period also 
includes the opening of K+-channels, causing an efflux of K+-ions, which hyperpolarize 
the membrane potential leading to de-inactivation of the Na+-channels. The sodium-
potassium pump exchanges Na+ for K+ and restores their initial concentrations. The 
membrane potential then returns to its original value, i.e. the resting potential. The action 
potential propagates along the nerve cell at velocities between 0.5 and 150 m/s,
depending on the type of nerve cell [33].
Table 2.1. Extracellular and intracellular ion concentrations for a human skeletal muscle 
cell and their respective thermal equilibrium potential. Adapted from Hille [31]
Ion Extracellular concentration 
(mM)
Intracellular concentration 
(mM)
Equilibrium 
potential (mV)
Na+ 145 12 67
K+ 4 155 -98
Ca2+ 1.5 10-7 129
Cl- 123 4.2 -90
Ion channels contain many conserved regions and share several structural features. The 
pore region is usually comprised of multiple membrane-spanning segments, either 
originating from heterooligomeric or homooligomeric subunits, or from a single 
polypeptide chain with repeating transmembrane motifs [34]. The membrane-spanning 
regions are linked by hydrophilic loops that extend either on the intracellular or the 
extracellular side of the membrane. 
Ion channels are often classified depending on their opening mechanism. Resting
channels or leak channels are always open, e.g. certain K+-channels, and they influence 
the resting membrane potential [34]. Gated channels open upon certain stimuli such as a 
change in voltage, binding of a ligand, change in temperature or mechanical stress [27].
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Figure 2.3. The α-helices enclosing an ion channel pore undergo a large structural rearrangement 
between the open and closed states of the ion channel. During activation, only specific ion species 
are allowed to pass through the pore.
Many ion channels rely on a specific lipid composition for their function, e.g. cholesterol 
is important for the function of several types of ion channels [35]–[40]. The effect of 
cholesterol levels on ion channel function has often been tested with the use of 
cyclodextrins, cyclic oligosaccharides that can both deliver or extract cholesterol from the 
cell membrane [41].
2.3.1 Membrane potential
Two main forces are governing the flow of ions across the cell membrane, the electrical 
potential of the cell membrane and the diffusive force down a concentration gradient [31].
The equilibrium potential when these two forces cancel out and there is no net movement 
of ions is called the reversal potential or the thermodynamic equilibrium potential. It is 
given by the Nernst equation: = [ ][ ] Eq. 1
where is the equilibrium potential for the ion S, is the gas constant, is the 
temperature, is the ion-valency, is Faraday's constant, [ ] is the concentration of S 
on the intracellular side and [ ] is the concentration of S on the extracellular side [31].
OpenClosed
Ions
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The membrane potential of a cell is a result of the equilibrium potential of all the ions that 
constitutes the intracellular and extracellular environment, as well as the permeability of 
the different ion species through the cell membrane which is dependent on the opening 
and closing of ion channels. The membrane potential can e.g. be calculated using the 
Goldman-Hodgkin-Katz equation: 
𝐸𝑚 = 𝑅𝑇𝐹 𝑙𝑛 �∑ 𝑃𝑀𝑖+[𝑀𝑖+]𝑜𝑢𝑡𝑁𝑖 +∑ 𝑃𝐴𝑗−[𝐴𝑗−]𝑖𝑛𝑁𝑗∑ 𝑃𝑀𝑖+[𝑀𝑖+]𝑖𝑛𝑁𝑖 +∑ 𝑃𝐴𝑗−[𝐴𝑗−]𝑜𝑢𝑡𝑁𝑗 �  Eq. 2 
where 𝐸𝑚 is the membrane potential, 𝑅 is the gas constant, 𝑇 is the temperature, 𝐹 is 
Faraday's constant, 𝑃 is the ion specific permeability and 𝑀+ and 𝐴− are cations and 
anions, respectively [31]. 
K+-channels are generally the only ion channels open during the resting stage of the 
membrane. Hence, the cell membrane is only permeable to K+-ions and the resting 
potential becomes equal to the reversal potential of K+. 
2.3.2 Ion permeability and selectivity 
The rate by which an ion species will pass through an open ion channel is given by its 
permeability. The selectivity of an ion channel is in turn a description of how the 
permeability of different ions is relative to each other. Ion channels are in general highly 
selective for only one type of ion, while other ion species have low permeability, and ion 
channels are as a result often grouped into families based on the main ion which they 
conduct. The mechanism by which this selection occurs varies between ion species but is 
mainly accomplished by a sequence of amino acids inside the pore domain, defined as the 
selectivity filter [32]. The selectivity filter in K+-channels is the most studied. The pore in 
a K+ channel is lined with the amino acid sequence TVGYG which constitutes four 
binding sites that are selective for K+ [42], [43]  
  
Relative ion permeabilities can be determined experimentally by measuring and
comparing the reversal potentials for two different ions. The reversal potential for the ion 
X and Y are given by: = [ ][ ] Eq. 3
and = [ ][ ] Eq. 4
By subtracting the equation for ion X with the equation for ion Y we obtain how the 
difference in reversal potential relates to the permeability of ion X compared to ion Y [31].
∆ = , − ,  = [ ][ ] Eq. 5
where is the permeability for ion Y, is the permeability for ion X, [ ] and [ ]
are their respective extracellular concentration, ∆ is the difference in reversal 
potential between ion X and ion Y, is the gas constant, is the temperature, is 
Faraday's constant and is the ion valence.
In permeability studies of ion channels, the extracellular concentration can commonly be 
controlled during measurements of ion channel activity and the reversal potential is 
determined using patch-clamp recording. The ion channel is subjected to a range of 
different membrane potentials and the potential at zero net current is the reversal 
potential.
2.3.3 Transient receptor potential vanilloid 1
The transient receptor potential vanilloid 1 (TRPV1) is an ion channel primarily 
expressed in dorsal root ganglia and trigeminal ganglia where it mediates nociception 
upon activation with various noxious stimuli. TRPV1 was first cloned in 1997 by 
Caterina et al. [44] after the discovery that certain sensory neurons responded to 
capsaicin, the pungent compound in chili peppers. It has since then been established that 
TRPV1 can be directly activated by capsaicin but also by low pH, high temperatures 
(T>42°C), anandamide, lipoxygenase products and N-arachidonyldopamine [44]–[50].
12
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TRPV1 is a polymodal ion channel since it has the ability to respond to a wide range of 
noxious stimuli, e.g. chemical and thermal. TRPV1 is also responsible for inflammatory 
hyperalgesia which is an increased pain sensitivity towards noxious stimuli [51]. 
Inflammatory mediators such as, bradykinin [52], [53], extracellular ATP [54], nerve 
growth factor [53] and glutamate [55], are responsible for this effect since they can 
indirectly sensitize TRPV1 and lower its activation threshold toward chemical and 
thermal stimuli. 
TRPV1 is a multimeric protein, consisting of four identical monomers. Each of the 
monomers has six transmembrane (TM) regions with the fifth and the sixth TM-regions 
positioned in the protein centre, enclosing the ion channel pore (Figure 2.4). The N- and 
C-termini of TRPV1 are located on the intracellular side of the cell membrane, 
comprising roughly 70% of the protein mass. This structural arrangement of TRPV1 has 
been determined largely based on similarities with the Kv1.2 channel [56], [57]. These 
models have been further validated with experimental data, using electron 
cryomicroscopy [58], [59]. 
The molecular mechanisms for TRPV1-activation with capsaicin, protons and heat are 
very different. Capsaicin is a hydrophobic molecule that can diffuse through the cell 
membrane. It activates TRPV1 through interaction with amino acids both in the TM-
regions [60]–[62] as well as the N- and C-terminus [63], [64]. Protons activate and 
potentiate TRPV1 solely on the extracellular side where amino acids in the linker 
between TM-region 3 and TM-region 4, as well as inside the pore, have been shown to be 
important [46], [65], [66]. The mechanism by which temperature activation occurs is less 
characterized, but several regions have been implied to be involved in temperature gating, 
including parts of the C-terminal and an extracellular region referred to as the pore turret 
[56], [64], [67], [68]. 
TRPV1 is not only polymodal in its activation mechanisms but also in its selectivity. 
TRPV1 is permeable both to monovalent and divalent cations but with higher selectivity 
for divalent cations, especially Ca2+. The permeability sequence has been determined for 
TRPV1 as Ca2+ > Mg2+ > Na+~ K+ ~ Cs+ [44]. 
14 
 
TRPV1 will desensitize, i.e. lose its activity upon constant application of a stimulus, in 
the presence of Ca2+. The protein calmodulin has been proposed to be responsible for this 
mechanism by binding to the intracellular side of TRPV1. Two calmodulin binding sites 
have been determined, one in the N-terminus and one in the C-terminus [69]–[71].
If there are no Ca2+-ions present, then TRPV1 will undergo a time-dependent increase in 
permeability towards large cations, which is referred to as pore dilation [72]. This 
phenomenon is exclusive for a few ion channels, including TRPA1 and P2X [73]–[78].
Figure 2.4 A schematic representation of a TRPV1 monomer (top) and their tetrameric 
arrangement (bottom). TRPV1 consists of four identical monomers, here colored in alternating 
blue and orange. Their organization residing in the cell membrane are here viewed from the side 
(bottom left) and from the extracellular side (bottom right)
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TRPV1 is regarded to be an important drug target due to its role in pain reception and 
hyperalgesia [51], [79], [80]. Considerable efforts have been made to characterize its 
functional regions [81]. Molecules completely blocking TRPV1 activity have, however,
hadso far little therapeutic success. The ion channels sensitivity toward high 
temperatures was found to be an important regulator of basal body temperature, because 
complete blockade of ion channel response causes hyperthermia as a side-effect [82], 
[83]. More knowledge about this complex ion channel is needed in order to develop drugs 
that target specific pathways leading to hyperalgesia but not its normal physiological 
response.
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3
ANTIBODIES
Antibodies are large, Y-shaped proteins that bind to and neutralize invading pathogens. 
They are produced by the adaptive immune system and developed to recognize foreign 
proteins by binding to specific sequences on the surface of these proteins [84]. Proteins 
that are capable of triggering an immune response and subsequent binding of antibodies 
are referred to as antigens, and the region of the antigen that is targeted by the antibody is 
referred to as an antigenic determinant or epitope [27].
Antibodies have the capabilities, beside binding and recognizing the antigen, to recruit
other components of the immune system with the purpose of destroying the foreign entity. 
The tail of the antibody, called the Fc-region, can bind to receptors on the surface of 
different effector cells. Examples are effector cells that release toxic molecules and cause 
lysis of the target cell, or phagocytic cells, like macrophages and neutrophils, that ingest 
and destroy the antigen upon binding to the antibody. The antibodies can also bind to 
receptors on mast cells. Mast cells secrete cytokines and amines that dilate blood vessels, 
increasing the accessibility for immune cells to reach the infected site [27], [85].
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The immune system is capable of producing antibodies with a vast diversity in order to be 
ready for any invading pathogen. Antibodies are synthesized by B-cells with each cell 
expressing just a single type of antibody with a unique antigen-binding site. In an early 
stage of B-cell development, the B-cell will express an antibody, targeting a random 
antigen, located on its cell surface. When a particular antigen invades for the first time, 
only a few antibody displaying B-cells will have antibodies that matches the structure of 
the antigen and can bind to an antigenic determinant on its surface. These B-cells will, 
however, be triggered by the binding and start to differentiate into larger effector cells, 
capable of producing and secreting large amounts of antibody, up to 2000 molecules per 
second [27]. Some of the B-cells will differentiate into memory cells. These are cells that 
will recognize the antigen if it appears a second time and will be able to produce and 
secrete antibodies at shorter time scales as well as provide immunological memory for a 
lifetime [27]. This diversity and selectivity of antibodies is crucial for our ability to 
defend ourselves against infection with harmful pathogens. Severe defects in the adaptive 
immune system can cause otherwise harmless infections to become lethal.  
The immunological memory is the mechanism by which vaccines provide protection 
against infectious diseases. Vaccines are based on the introduction of a pathogen, or parts 
of a pathogen, into the body in a form that have been rendered inactive or weakened [86]. 
The vaccine components are chosen based on their immunogenicity, that is their ability to 
trigger an immune response but without causing a contagious or harmful version of the 
disease. The immune system will, as a result, produce antibodies against the pathogen 
after the vaccination event, and the pathogen will be directly recognized and destroyed 
during any subsequent infection. The first widespread use of a vaccine began in 1796, 
when Edward Jenner started performing vaccinations against smallpox using the cowpox 
virus originating from the same family. This finally led to the eradication of the disease in 
1980 [87].  
A technique to produce antibodies in host animals was developed in the 1970s [88], 
which has led to a rapidly growing field where antibodies are used as disease therapies. 
Such antibody therapies rely on the capabilities of antibodies to selectively bind to a drug 
target. A method for selection of antigenic determinants within a target protein and 
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subsequent generation of antibodies for therapeutic purposes was developed within the 
work that contributed to this thesis. 
3.1 Structure 
Antibodies belong to a class of proteins called immunoglobulins (Ig). These are globular 
proteins weighing roughly 150 kDa. The structural arrangement of an antibody is 
comprised of four monomers, two light chains and two heavy chains, held together in a 
Y-shaped structure by non-covalent bonds and disulfide bridges (Figure 3.1). Each 
antibody has two identical antigen binding sites, formed by one light chain and one heavy 
chain. The heavy chains are longer, 440 amino acids compared to 220 amino acids for the 
light chains. The exceeding parts of the heavy chains bind together and form the tail part 
of the antibody, called the Fc-region. This region binds to receptors on mast cells and 
phagocytes [27], [89]–[91]. 
The N-termini of the light and heavy chains are located in the antigen binding sites. These 
four ends each consist of a 110 amino acid-long variable region that are the key parts 
responsible for antigen binding. They are highly diverse in their sequence, allowing for 
many structural differences so that a matching antibody will exist for each possible 
antigen. Three segments on each variable chain serve as the actual binding site. They are 
called hypervariable loops and are 5-10 amino acids long [27], [89]–[91]. The 
corresponding binding site on the antigen is small compared to the actual size of the 
antibody, usually ~25 amino acids [27]. The parts of the antibody not located in the 
variable regions are called constant regions. There exist five different subclasses of 
immunoglobulins: IgA, IgD, IgG, IgE and IgM, each with a distinctive constant region of 
their heavy chains [27], [89]–[91]. 
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Figure 3.1 Schematic representation of an antibody structure. The heavy and light chains are 
colored in blue and purple respectively. The variable region of each chain is shaded in a lighter 
color. 
3.2 Antibody therapeutics
Antibody therapeutics utilize nature's own capability to develop highly specific molecules 
able to bind to any protein target of interest. The first therapeutic antibody, Orthoclone, 
was FDA-approved in 1985 [92]. Antibodies as therapeutic molecules have since then 
emerged, being now the fastest growing class of therapeutic drugs [25], which includes
successful drugs such as Humira (adalimumab, Abbott), Rituxan (rituximab, Biogen-
Idec), Avastin (bevacizumab, Roche) and Remicade (infliximab, Janssen) [93]. These 
drugs were initially approved for rheumatoid arthritis, non-Hodgkin's lymphoma, colon 
cancer and Chrohn's disease, respectively, but have all been approved for other 
indications as well.
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The mechanistic action of antibody drugs varies with each antibody and depends on the 
target protein of interest, e.g. an antibody may be able to abolish or decrease the activity 
of the target protein by steric hindrance upon binding. The antibody drug can also be 
designed to utilize the mechanism by which the Fc-region can bind to immune cells and 
trigger destruction of the antibody target. This is a common strategy for antibody derived 
cancer therapies where the antibody is designed to recognize and bind to antigens 
expressed on tumor cells [85], [94].    
3.2.1 Development 
A method for laboratory production of antibodies was first developed in 1975 and is 
called the hybridoma technique [88]. Mammals, usually mice, are injected with an 
antigen that triggers their immune response in order to start producing antibodies 
targeting the antigen. This process of introducing the antigen is called immunization. B-
cells from the animal's spleen are then removed and subsequently fused with 
immortalized myeloma cells, which are cancerous B-cells. The fused cells are termed 
hybridomas and they have acquired the ability to proliferate indefinitely from the 
myelomas. The hybridomas are diluted down to single cells and separated into multi-well 
plates where they are further cultured into antibody producing colonies. Since one B-cell 
give rise to each separate colony, the produced antibodies in a single well will be 
identical, hence, called monoclonal antibodies.  
The hybridoma technique will give rise to hundreds of different antibody producing B-
cell cultures, with each antibody having a different antigen affinity and biological 
efficacy. These cultures need to be screened in order to find the most suitable candidate 
for drug development. The first step is to test the ability of the antibodies to bind to the 
antigen. This is done using antibody capture/antigen capture techniques, such as the 
enzyme-linked immunosorbent assay (ELISA), where the antigen is immobilized on a 
solid support and then subjected to an antibody. Binding between antigen and antibody is 
confirmed using a secondary antibody: a tagged antibody that is chosen to recognize the 
constant antibody regions from the species that produced the primary antibody. Other 
commonly used screening techniques are radioimmunoassays and immunofluorescence 
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[95]. The antibodies providing the highest ELISA signal are further evaluated for their 
biological efficacy using methods that are largely dependent on the type of antigen. 
The first antibody therapies developed using the hybridoma technique were initially not 
very successful. Antibody drugs produced in murine hosts contain murine amino acid 
sequences that are recognized as foreign by the human immune system, thus triggering 
the production of human anti-mouse antibodies causing mild to lethal side effects [96]. 
Since then, advances have been made in order to minimize the murine content in 
therapeutic antibodies. Chimeric antibodies were the first attempt where the Fc-regions of 
the murine antibody was switched to its human counterpart [97]. This resulted in ~65% 
human sequences, and less, although not eradicated immunogenicity [98]. Further 
development have resulted in humanized antibodies with amino acid sequences that are 
~95% human [99], [100]. Remaining exceptions are the hypervariable regions of the 
antigen binding site that remain murine. Fully human antibodies are now also possible. 
Transgenic mice containing human genes encoding for the heavy and light chains will 
produce human antibodies upon immunization  [101], [102]. These advances in antibody 
technologies have led to a decrease in immunogenicity, and caused this therapeutic field 
to grow rapidly. 
Today, strategies towards developing and finding successful immunotherapies are not 
limited to full size monoclonal antibodies. Due to advances in protein engineering, a wide 
variety of engineered antibody fragments (Figure 3.2) have been derived during the two 
last decades, including Fab fragments, ScFv fragments, diabodies, tetrabodies, antibody 
fragments functionalized with protein conjugates as well as bispecific fragments binding 
to two antigens [103], [104]. These new constructs provide a much larger toolbox when 
trying to develop antibodies and antibody-derived biologics with high specificity and 
affinity, deep tissue penetration, high stability and low toxicity.  
An advantage with smaller antibody fragments compared to full size antibodies is that 
they can be produced in different expression systems, e.g. E. coli, yeast and mammalian 
cells, and are no longer limited to production with the hybridoma technique. This enables 
large scale production at lower cost. and provides many possibilities to genetically 
modulate antibody properties [105]. Antibody fragments can be displayed on the surface 
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of the filamentous bacteriophage, a so called phage display, used to create large antibody 
libraries which are screened against the desired antigen [106]. The screening procedure 
evaluates which antibody candidates are binding the antigen. It is often repeated in 
several cycles due to unspecific binding in the first cycles. The conditions during the 
screening cycles can be changed in order to find the best suitable candidates for a certain 
environment, e.g. more stable antibodies can be selected by using a harsh environment. 
Another method to select antibodies with very high affinity is to perform the screening 
with very low concentration of antigen so that only those antibodies capable of binding 
during such conditions, remain [107].
Figure 3.2 A selection of smaller antibody fragments developed from a full size antibody or 
through genetic engineering.
3.2.2 Antibody delivery
One of the main hurdles with antibody therapies is their restriction to extracellular targets. 
Antibodies are too large and too polar to enter through the cell membrane and are, 
generally, unstable in the reducing environment of the cytosol [108]. Several techniques 
have been developed in order to access intracellular targets, including transport of 
antibodies across the cell membrane with different transport vectors, e.g. protein 
transfection (profection) reagents and protein transduction domains (PTDs), as well as the 
expression of the antibody directly within the target cell, so called intrabodies [108].
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Intrabodies can be constructed to target different cellular compartments by fusing the 
genetic sequence of the intrabody with intracellular trafficking signals. The need for 
efficient delivery methods is nonetheless a crucial step in intrabody therapy since the 
genetic material encoding the intrabody still needs to be delivered to the target cell [109]. 
Delivery of genetic material, drugs and proteins through electroporation have been widely 
used since its discovery in the 1980s [110]. Electroporation is a method by which 
transient pores are introduced in the cell membrane when applying an electrical pulse, 
facilitating uptake of exogenous substances. It has been used clinically for delivery of 
chemotherapeutic drugs to tumors [111], [112] and several DNA vaccines are in clinical 
trials using electroporation as the delivery method [113]. Electroporation of antibodies 
has not been as extensively studied as electroporation of chemicals and genetic material, 
but several groups have managed to electroporate and deliver antibodies with high 
viability of the electroporated cells [114]–[116]. Marschall et al., recently compared 
electroporation of antibodies to internalization through protein transduction domains and 
profection agents, and found electroporation to be superior [117].   
Electroporation was used in the work performed for this thesis for intracellular delivery of 
antibodies designed to bind to the intracellular part of the ion channel TRPV1. 
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4
THE PATCH CLAMP TECHNIQUE
The currents mediated by ion channels upon their opening are extremely small, in the 
picoampere range, and may occur just for a few milliseconds. Patch clamp recording is an 
electrophysiological technique which was developed with the purpose of studying the 
electrical properties of ion channels in live cells. The technique is sensitive enough to 
register the small currents flowing through a single ion channel. It was developed by 
Erwin Neher and Bert Sakmann in 1976 [118] for which they were awarded the Nobel 
prize, and was further refined into the technique still used today, in 1981 [119].
Patch-clamp was used within this work to study the function of the TRPV1 ion channel.
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4.1 Recording configurations and circuits 
The principle of the patch clamp technique is to form a high resistance seal, a gigaseal 
(> 1 GΩ), between the tip of an electrolyte-filled glass micropipette and the cell 
membrane. This tight junction, prevents currents from escaping at the micropipette tip 
and is a prerequisite for low noise recordings of currents flowing through the cell 
membrane. A patch-clamp amplifier that is connected with the cell through two 
electrodes, one inserted in the electrolyte-filled micropipette and one reference electrode 
located in the bath solution surrounding the cell, is used to measure and control the 
electrical properties of the cell [120].  
Patch clamp recordings can be performed in four different configurations, i.e. cell- 
attached, whole-cell, inside-out and outside-out (Figure 4.1). These different 
configurations allow for electrophysiological recordings of either a population of ion 
channels or single ion channels. The cell attached patch configuration is the configuration 
when a single cell is attached to the micropipette with a gigaseal. The configuration is 
achieved by approaching the cell with the micropipette, aided by a light microscope. 
When the pipette touches the membrane, a negative pressure is applied, causing a small 
part of the membrane to get sucked into the tip, forming a seal. Using this configuration, 
measurements can be made on ion channels residing in the membrane patch that covers 
the pipette tip which can be single channels depending on the protein expression level and 
size of the pipette tip. This configuration allows for recordings to be made of ion channels 
in their normal cellular environment, but the membrane potential and the cytosolic 
solution cannot be precisely controlled. The cell attached configuration serves as a 
starting point for both the whole cell configuration and the inside-out configuration. If the 
pipette tip is slowly removed from the cell attached configuration, then a part of the 
membrane will be torn away and remain sealed to the pipette tip. This is called the inside-
out configuration, since the inside of the membrane is exposed to the surrounding bath 
solution. This is also a technique to achieve single channel recordings while the 
intracellular side of the membrane can be exposed to different types of solutions. 
Applying a slight suction, or negative pressure, during the cell attached configuration, 
will produce a rupture of the cell membrane beneath the pipette tip, and the measuring 
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electrode will be in direct contact with the cytosol via the electrode buffer. This 
configuration, whole-cell recording, will measure all ion channels simultaneously while 
the membrane potential can be precisely controlled or clamped. The last configuration is 
the outside-out configuration. When in the whole-cell configuration, one can remove the 
pipette tip from the cell. This will tear a part of the membrane away from the cell. This 
membrane patch will reseal and form a small vesicle at the pipette tip. Now, the 
extracellular part of the membrane is exposed to the bath solution. This configuration is 
useful when performing single channel recordings and the ion channel is modulated from 
the extracellular side [120].
Figure 4.1 Different patch-configurations that can be achieved from the on-cell position by 
applying suction or by removal of the pipette. The arrows denote the ion flow direction.
Here exemplified for an ion channel which normally cause an influx of ions.
Recordings of ion channel activity can be performed using two different setups; the 
voltage-clamp or current-clamp modes. In current-clamp mode, the current is held 
constant while the membrane potential is measured. This method is commonly utilized 
for the measurement of action potentials mediated by voltage-dependent ion channels. In 
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voltage-clamp mode the membrane potential is held constant while the current is 
measured. In order for the membrane potential to be constant, the patch clamp amplifier 
will continuously measure the potential and compare it to a set value, the holding or 
clamp potential. If it deviates, the amplifier will inject a small current to compensate for 
the difference. During activation of an ion channel, the membrane potential will change 
due to the current. The amplifier will then compensate with the same amount of current, 
but in opposite direction, in order to keep the membrane potential constant. The injected 
current is then equal, but with the opposite sign, to the current conducted by the ion 
channel, and is the current recorded by the amplifier.
Several parameters of the patch clamp setup can influence the recordings and can give 
rise to errors during the measurements that need to be minimized. The membrane itself 
acts as an insulator between the cytosol and the bath solution. It then behaves as a 
capacitor (Cmembrane) that can store charge but also as a resistor (Rmembrane) since it contains 
ion channels that can transport charges upon opening. An equivalent circuit for a whole 
cell configuration is shown in Figure 4.2. The interior of the pipette will act as a resistor 
(Rpipette) and the glass wall a capacitor (Cpipette). In addition the pore between the pipette 
tip and the cytosol will also act as a resistor contributing with the access resistance
(Raccess). The access resistance is configured in series with the pipette resistance and 
together with the membrane capacitance it forms an RC circuit. These parameters 
influence the measurements by causing delays during voltage changes. The amplifier has 
the capability to compensate for some of these factors, but it is important to minimize 
these resistances, e.g. by using low resistance glass pipettes with a large tip [120].
Two of the configurations described above, i.e. whole-cell and inside-out, were used 
within the work of this thesis to record current responses mediated by the TRPV1 ion 
channel. The voltage clamp mode was utilized in order to measure current amplitudes, 
reversal potentials and EC50-values. The EC50 -value for an ion channel agonist is the 
concentration of this agonist activating a half maximal current response recorded by one 
of the configurations described above. It is experimentally determined by measuring 
current responses activated by a number of different agonist concentrations. The currents 
responses are fitted against a dose-response curve, commonly a four-parameter sigmoidal 
function.
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Figure 4.2 Equivalent circuit of a whole-cell patch configuration
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5
PROTEOMICS
The proteome of an organism or a cell is its entire set of proteins, expressed at a given 
time. The term was first coined by Marc Wilkins in the 1990s [121] in alignment with the 
term used to describe the genetic material of an organism, the genome. While the genetic 
material of an organism is constant, the proteome is highly dynamic, with the number and 
identity of proteins being expressed varying greatly with time. The study of the proteome,
i.e. how proteins are expressed, how they interact and how they are modified, is called 
proteomics [122], [123]. One of the first techniques to be used for large scale protein 
analysis was two-dimensional gel electrophoresis [124]. However, it has now been
largely replaced by mass spectrometry as the gold standard for proteomic analysis [125], 
[126].
Mass spectrometry was used within the work of this thesis to identify proteins and 
peptides, the principles of which are both described below.
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5.1 Mass spectrometry in proteomics  
Mass spectrometry is the most widely used technique in proteomics and is used for 
analysis of protein identity, protein sequencing, studies of post translational modifications 
(PTMs) and protein interactions [127]–[129].  
The mass spectrometer analyzes molecules based on their mass and charge, more 
specifically their mass to charge ratio (m/z). Ionization is the first step where the analytes 
aquire one or more charges. The generated ions are then detected based on their mass to 
charge ratio inside a mass analyzer. The number of ions for each m/z is detected and the 
output is a mass spectrum with the intensity of each ion plotted against its mass to charge 
ratio. Initially, the method was limited to small volatile compounds but in the mid 1980s 
two new ionization techniques were developed, matrix-assisted laser desorption 
ionization (MALDI) [130] and electrospray injection (ESI) [131] that can be used on 
biomolecules. Since the development of these ionization techniques, the field of mass 
spectrometry-based proteomics has expanded rapidly, with a continuous development of 
more accurate and sensitive equipment with higher resolving power.  
There are several different types of mass analyzers that can be used for proteomics, such 
as time of flight (TOF) mass analyzers, quadrupoles, ion traps (quadrupole and linear), 
orbitraps and Fourier-transform ion cyclotron resonance (FT-ICR) mass analyzers. It is 
also common to use these instruments in combination with each other [127], [132], [133]. 
5.1.1 Protein identification and peptide sequencing 
Mass spectrometry based proteomics is generally performed either using a top-down or a 
bottom-up approach. Top-down mass spectrometry analyses entire proteins and is e.g. 
used for the study of peptide hormones [134] and PTMs [135]. The bottom-up approach, 
which is more common, performs the analysis on small peptides rather than entire 
proteins. A protease, commonly trypsin, can be used to degrade the protein into smaller 
peptides before analysis [133]. The generated peptides are separated, commonly using 
liquid chromatography (LC), and then identified with the mass spectrometer using a 
process called peptide mass finger-printing (PMF). Large databases have been 
established, where all known protein sequences for an organism have been in silico, i.e. 
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theoretically, digested with different proteases. The masses of the peptides are then 
compared to the in silico digested proteins in order to match them to the correct protein. 
Detection of several peptide masses matched to the same protein is needed for a true 
identification [136]. An advantage with this technique is that peptides are more easily 
ionized than entire proteins, thus yielding an increased sensitivity. Peptides are generally 
easier to dissolve and they are in a mass range suitable for mass spectrometric analysis 
[137]. However, two peptides of equal masses cannot be distinguished from each other, 
which can easily occur in digests from protein mixtures. 
To further aid the identification of a protein, mass spectrometry can be used to determine 
the protein amino acid sequence by utilizing a mass spectrometer working in tandem, 
either with several separate mass analyzers or with one mass analyzer, cycling between 
detection modes. First, the mass analyzer separates the peptide parent ions based on their 
mass to charge ratio. One peptide parent ion at a time is then fragmented into smaller 
ions, often using collision-induced dissociation (CID), a method where the peptides 
fragment upon collision with an inert gas [138]. The collision causes fragmentation to 
occur primarily at the peptide backbone and at three different sites. This can yield six 
different ion types depending on which side the charge remains after fragmentation as can 
be seen in Figure 5.1. These ions are named a, b, c and x, y, z according to the 
nomenclature developed by Roepstorff-Fohlmann-Biemann [137]. Using CID will mainly 
yield b- and y-ions. B-ions have the charge retained on the N-terminal side of the 
precursor ion and y-ions have the charge retained on the C-terminal side. All the 
fragments from each peptide type are separated based on their mass to charge ratio in the 
mass analyzer. The produced spectra can be used to determine the sequence of the 
specific peptide. In theory, if all possible b- and y-ions are present from a peptide, the 
sequence can be determined by comparing the mass difference between each peak in the 
spectrum. Each difference will correspond to the mass of an amino acid. This method of 
determining the protein sequence directly from the fragment spectra is called de novo 
sequencing [139]. However, all b- and y-ions are in reality rarely present but are 
accompanied by fragments such as immonium ions and others caused by e.g. neutral loss 
of water or ammonia [136], [140]. De novo sequencing thus requires careful analysis of 
each spectra and is less suitable for high-throughput screening with bottom-up mass 
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spectrometry. These limitations can be overcome by matching the mass spectrum with 
databases of known protein sequences. Even if the sequence of a peptide is incomplete it 
can still be unique, only matching the sequence of a single protein. The databases are 
searched using different algorithms such as MASCOT [141], SEQUEST [142] and
X!TANDEM [143].
A problem with assigning peptide and protein identities based on partial peptide 
sequences is the risk of false positives. Several of the search engines score each peptide 
match based on how well the fragment spectra matches the database spectra. An
additional method in order to limit false positives is to search the mass spectra against a 
decoy database, e.g. using the reversed sequences of the predicted peptides. A threshold 
for a false discovery rate (FDR) can be applied to the dataset. This gives an estimate on 
how many fragment spectra that are matched against false peptides. [144], [145].
Figure 5.1 Peptide fragments according to the nomenclature developed by Roepstorff-Fohlmann-
Biemann
A limitation with bottom-up proteomics is that full sequence coverage of a protein is
rarely achieved, leading to loss of information regarding protein isoforms, such as 
alternative splicing and PTMs. The top-down proteomic approach has instead been 
utilized for such studies of protein modifications where entire proteins are analyzed and 
fragmentation of the protein occurs inside the mass spectrometer. This is in contrast to 
bottom-up proteomics, where proteins are digested prior to analysis [146]. This yields
data with potentially full sequence coverage, suitable for investigations of even small 
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variations in protein structure. The spectra produced after fragmentation of entire proteins 
are, however, much more complex than spectra achieved from fragmentation of peptides. 
High resolution mass spectrometers are thus needed for top-down proteomics, and the 
ability to analyze protein mixtures, as well as high throughput proteomic profiling, is 
limited [147], [148]. Another drawback is that larger proteins (>50 kDa) are more 
difficult to fragment [147], [149] which has restricted the use of top-down mass 
spectrometry to smaller proteins. Bottom-up mass spectrometry has thus been more 
widely used within the proteomics field but technical advances in instrumentation and 
separation techniques have led to an increasing interest in top-down mass spectrometry.
These advancements resulted in the development of techniques for studies of larger 
proteins [150], as well as complex protein mixtures [151], using top-down mass 
spectrometry.
5.2 Limited proteolysis
Membrane proteins are important drug targets, but their hydrophobic parts complicate
elucidation of their structure, information that could facilitate drug development to these 
targets. Several membrane proteins, however, contain hydrophilic regions on one or both 
sides of the cell membrane. Identification of surface residues within these hydrophilic 
regions is not only useful when determining protein structure, but also an important 
parameter when predicting ligand binding sites [152]. Limited proteolysis in combination 
with mass spectrometry is a suitable method to evaluate surface topology of a protein, by
restricting the activity of a protease to digest only the most flexible and surface-exposed
parts. This can be achieved, specifically, by controlling the activity of a protease using 
e.g. low temperatures, low concentrations and/or short digestion times followed by 
identification of the digested regions with mass spectrometry [153]–[155].
When limited proteolysis has been performed on proteins with known structure, mainly 
three structural determinants have been recognized as having impact on the sites of 
proteolytic activity, namely flexibility, surface exposure and local interactions [154], 
[156], [157]. In order for the peptide chain to enter the active site within a protease, 
flexibility and the ability to locally unfold is required. Surface exposure renders a 
cleavage site more likely for proteolysis. This is due to the fact that regions at the surface
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tend to more easily unfold as well as impose less steric hindrance on the protease. Finally,
the amount of local interactions, like hydrogen bonds and disulphide bridges determines 
the rate of proteolytic activity. Less local interactions favor proteolysis. All three of these 
structural determinants are usually correlated within the protein. Hence, limited 
proteolysis will mainly cleave surface exposed regions given that the protein chain can 
unfold locally. It has been used as a method to determine flexible regions in proteins with 
unknown detailed structure [153], [158], [159], as well as to identify stable regions 
resistant to proteolysis and suitable for crystallization [160], [161].
5.3 Proteoliposomes
The occurrence of a proteolytic event during limited proteolysis is determined by the 
tertiary structure of the protein rather than the amino acid sequence, hence a native, 
correctly folded structure is crucial. When performing limited proteolysis on membrane 
proteins, they need to be situated in a lipid environment in order to be correctly folded 
and for proteolysis to yield useful structural information. A common method to protect 
the native structure of membrane proteins is to maintain them in lipid vesicles. Such 
proteoliposomes can be reconstituted from purified membrane proteins and lipids [162], 
[163] or be directly derived from the cell membrane e.g. through blebbing [164], [165] or 
through lysis of the cell [166]. An advantage of using proteoliposomes derived directly 
from the cell membrane is that they contain the correct lipid composition for membrane 
protein function as well as other interacting proteins and co-factors. However, when
performing limited proteolysis on proteoliposomes, fast and sensitive mass spectrometers 
are required since the proteolytic peptides will originate from several hundreds of proteins 
residing in the proteoliposome as well as membrane associated proteins.
Within this work, proteoliposomes were derived from Chinese hamster ovary (CHO) 
cells, expressing the human TRPV1 ion channel, by lysing the cells with mechanical 
disruption using a Dounce homogenizer [167], followed by centrifugation steps to remove 
nuclei and mitochondria. Proteoliposomes (50-150 nm in diameter) were subsequently
formed from this membrane fraction by tip-sonication (Figure 5.2). These 
proteoliposomes were used during functional and structural studies of TRPV1, e.g. 
evaluation of surface topology, using limited proteolysis.
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Figure 5.2 Schematic representation of proteoliposome preparation. Cells are cultured and 
harvested followed by lysis, using osmotic pressure and mechanical disruption. The lysed cells 
are then centrifuged in several steps to remove nuclei and mitochondria. Finally, proteoliposomes 
are formed from the remaining membrane fraction, using tip-sonication.
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Proteoliposomes
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6
OPTICAL MICROSCOPY
Microscopy is the technique of investigating objects that are too small to visualize with 
just the naked eye. Optical microscopes are the oldest class of microscopes and utilize 
light and a system of lenses to magnify the microfeatures of the specimen. The lateral 
resolution of optical microscopes, i.e. the smallest feature that can be distinguished, is 
dependent on the numerical aperture (NA) of the objective and the wavelength (˜) used to 
visualize the specimen, according to the Rayleigh criterion [168], [169]= 0.61 λNA Eq. 6
The numerical aperture is given by:NA = sin Eq. 7
where n is the refractive index of the media between the objective and the specimen and θ
is the half-angle of the maximum cone of light that can enter or exit the lens. The 
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refractive index is 1.0 for air, 1.33 for water and 1.56 for oil. Using an oil immersion 
objective together with a wavelength of 400 nm gives a resolution limit of ~200 nm. 
Optical microscopy has been used in this thesis work as visual guidance during patch-
clamp experiments and to detect and measure fluorescence with laser scanning confocal 
microscopy, the principles of which are both described below.  
6.1 Fluorescence 
Fluorescence is phenomenon where a molecule absorbs light and emits the acquired 
energy as light of a longer wavelength. The energy of a photon that is absorbed by a 
fluorescent molecule is inversely proportional to its wavelength and can be described as 
𝐸 = ℎ𝑐
𝜆
  Eq. 8 
where h is Planck's constant, c is the speed of light and λ is the wavelength.  
During absorption of a photon, the energy electronically excites the molecule from a 
ground state, S0, to a higher energy state, S1. At each of these electronic states, the 
energetically elevated electron in the molecule can exist at several different vibrational 
levels. These energy sub-states are transient and the molecule will rapidly relax back to 
the lowest vibrational level of the first singlet state S1, through vibrational relaxation. To 
further relax to the ground state S0, the molecule emits a photon. The emitted photon will 
have a longer wavelength than the absorbed photon due to loss of energy during 
vibrational relaxation. This shift in wavelength is called the Stokes shift [170]. The 
different electronic states of a fluorescent molecule can be visualized using a Jablonski 
diagram (Figure 6.1). 
Molecules that have the ability to fluoresce efficiently are called fluorophores. The 
efficiency of a fluorophore is given by its quantum yield, defined as the probability of an 
emitted photon per absorbed photon. It describes how well the energy from the incident 
light is converted to emitted light. The quantum yield of a fluorophore is generally 
dependent on its environment. Many fluorophores have a high quantum yield in aqueous 
solutions but there are also fluorophores that start to fluoresce efficiently, i.e. they exhibit 
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a rapid increase in their quantum yield, upon binding to other molecules, e.g. different 
ions. 
Fluorophores are used extensively in life science research, where they are mainly used to 
label different biological structures. Fluorophores that have been utilized in this thesis 
work are Fura-2, a calcium indicator which shows increased fluorescence upon binding to 
calcium [171]; YO-PRO, a dye that can pass through active TRPV1 ion channels and 
increases its quantum yield upon intercalation into DNA [72], [172]; and Alexa 488 [173]
which was tagged to goat anti-rabbit antibodies for studies using immunofluorescence.
Figure 6.1 A simplified Jablonski diagram showing absorption followed by vibrational relaxation 
and fluorescence. Electronic excitation to higher states and relaxation routes other than 
fluorescence are omitted.
6.2 Laser scanning confocal microscopy
A laser scanning confocal microscope is a microscope developed to visualize fluorescent 
specimens with improved resolution compared to conventional fluorescence microscopes. 
It is commonly used in biology to study both live and fixed cells. The specimen is excited 
with a laser that scans the illuminated area in a lateral motion. The light path of both the 
excitation and emission can be seen in Figure 6.2. The laser is reflected by a dichroic
mirror and focused onto the specimen by the objective. The emitted light is collected by 
the objective, passed through the dichroic mirror followed by a pinhole aperture before it 
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reaches the detector. During excitation, fluorophores in several layers of the specimen 
will be excited and emit light. This out-of-focus light blurs the collected image. The 
pinhole, is positioned in front of the detector so that only light that originates from the 
focal plane, is allowed to reach the detector. This removes out-of-focus light and 
facilitates the collection of sharp images, producing thin optical slices or sections of the 
specimen. A 3D-image of the specimen can be constructed if the optical sections are 
collected at varying heights thorough the sample and combined [168].
Figure 6.2 A simplified schematic illustration of the beam pathway in a confocal microscope. 
Only light emitted from the focal plane can pass the pinhole and reach the detector. Out-of-focus 
light ( ) is blocked by the aperture wall.
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6.3 Immunofluorescence
Immunofluorescence is a technique used to visualize different cellular components 
through targeting with fluorescently labeled primary and secondary antibodies (Figure 
6.3). Primary antibodies bind to an antigen within a protein, whereas secondary 
antibodies bind to another antibody. Visualization of cellular structures can be achieved 
by directly using primary antibodies with fluorescent tags, or indirectly with untagged 
primary antibodies that are subsequently recognized with fluorescently tagged secondary 
antibodies [174]. The secondary antibodies have been designed to bind to the constant
region of antibodies from another species, e.g. if the primary antibodies were raised in 
mouse, then the secondary antibodies are chosen to recognize the constant region of a 
mouse antibody. 
Antibodies cannot cross the cellular membrane so internal structures are difficult to stain 
in live cells. If the goal is to visualize internal structures, then the cells are commonly 
fixed [175]–[177], a process that cross-links proteins and permeabilizes the cell 
membrane. 
Figure 6.3 Direct and indirect labeling of cellular components using fluorescently tagged 
antibodies. Primary antibodies binding to the cell component of interest are fluorescently 
tagged and used for direct labeling. Untagged primary antibodies are used for indirect
labeling, where a secondary, fluorescently tagged antibody bind to the primary antibody. 
Direct
Indirect
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7
MICROFLUIDICS
Microfluidics describes the handling and manipulation of small volumes of fluid, 
picoliters to nanoliters, inside micrometer scaled channel systems. Fluids at such scales 
have different characteristics compared to macroscopic systems. Fluids in motion can be 
described with the Navier-Stokes equation [178]:+ ∙ ∇ = −∇ + ∇2 + Eq. 9
where is the velocity of the fluid, ρ is the density of the fluid, p is the pressure, ˜ is the 
viscosity of the fluid and F are the external forces acting on the fluid. The Navier-Stokes 
equation is an application of Newton's second law and describes an incompressible 
Newtonian fluid. It can be solved into a velocity field for some specific cases. The left 
hand side of the Navier-Stokes equation describes inertial forces and the right hand side 
describes forces acting on the fluid such as pressure and viscosity. 
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When inertial forces are high, the fluid will exhibit chaotic turbulent flow. However when 
inertial forces are low and viscous forces dominate the flow will become ordered and 
laminar. The ratio of inertial force to viscous force is described by the Reynolds number:= Eq. 10
where is the velocity of the fluid, ρ is the density of the fluid, η is the viscosity and L is 
the characteristic length of the channel. The viscous forces dominate and the flow is 
laminar when the Reynolds number is low. The transition between laminar and turbulent 
flow in a pipe occurs  around Re = 2040 [179]. During laminar flow, the fluid flows in 
parallel segments and mixing between layers occurs primarily through diffusion [180].
7.1 Superfusion
Superfusion is a technique for delivery of compounds to a tissue or cell through the use of 
a continuous flow over the tissue or around the cell. Rapid superfusion, i.e. the delivery of 
active compounds present in the fluid, is crucial for the study of fast biological processes 
such as kinetic studies of ion channels. The solution exchange around the cell expressing 
the ion channel needs to be faster than the activation time of the channel, otherwise any 
measured current will have a rise time that is dependent on the solution exchange. Early 
devices for fast solution exchange were fabricated from glass pipettes. One such device is
the ˜-pipette, which have an internal barrier and are thus capable of deliver two different 
solutions simultaneously [181]. Rapid solution exchange is achieved either by movement 
of the cell relative the pipette or movement of the pipette itself. The ˜ -pipettes have been 
extended into a multi-barrel system where several pipettes are used together to deliver 
multiple solutions. Today, cellular scale superfusion is mainly achieved through the use 
of microfluidic devices, owed to the precise manipulation of flows in such devices, the 
ability to handle and test many different solutions, and the small volumes of reactants 
needed in comparison to bulk experiments.
7.1.1 Dynaflow chip
Superfusion during the patch-clamp experiments described in this thesis was achieved 
using the Dynaflow chip series, commercially available through Cellectricon AB 
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(Mölndal, Sweden). They are either fabricated entirely in glass or in 
polydimethylsiloxane (PDMS) bonded to glass. These microfluidic devices have a pre-
defined number of sample reservoirs, 8 and 16 were used through this thesis, with each 
reservoir entering into an individual channel. The channels are arranged in a closely 
packed parallel array with exits into an open volume (Figure 7.1). The sample reservoirs 
are sealed with a lid connected to a pneumatic pump, generating a flow through each 
channel simultaneously upon application of positive pressure. The flow within the 
channels is laminar since it is maintained at a velocity keeping the system at low 
Reynolds numbers. The parallel flows exiting  into the open volume  then  exhibits  a 
pattern with sharp boundaries between each solution, for an extended distance of 10s of 
microns. The cell is patched inside the open volume and then lifted and translated using 
the patch pipette to the channel outlets. Rapid solution switching is achieved by 
movement of the chip relative to the cell ,  and switching times of ~20 ms are achieved.
Figure 7.1 Schematic representation of a Dynaflow chip containing eight sample reservoirs with 
parallel channels exiting into an open volume. Cells are patched inside the open volume with a 
patch pipette and then moved to the channel outlets for measurements.
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7.1.2 LPI flow cell 
A microfluidic cell with the aim of performing proteomic profiling of membrane proteins 
was developed and characterized during the work described in this thesis. The flow cell 
utilizes a lipid-based protein immobilization (LPI) technology, which enables membrane 
proteins situated in lipid vesicles to bind to the flow cell surfaces. By deriving 
proteoliposomes from cells and immobilizing them within the flow cell, a stationary 
phase of membrane proteins is created, which can be subjected to several sequential 
solutions and different types of chemical modulations, e.g. by enzymes. 
 
The flow cell is constructed from two gold-coated, parallel, polymer surfaces, separated 
by a 50 µm thick spacer. Each channel is 50 µm high, 5 mm wide and 95 mm long and 
has an inlet and an outlet port to be used with either manual pipetting or with a flow 
generated by, e.g., syringe pumps (Figure 7.2). The flow cell has a large surface to 
volume ratio that allows for fast solution exchange during laminar flow conditions. Fast 
solution exchange allows for short, controlled reaction times, which is a requirement for 
e.g., kinetic studies. The large surface to volume ratio enables much material to be 
immobilized on the internal surfaces of the cell, while minimizing dilution of, e.g., 
digested peptides during limited proteolysis of proteoliposomes.  
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Figure 7.2 Schematic representation of the LPI flow cell containing six different channels to be 
used for immobilization of proteoliposomes. Only vesicles adhered to the bottom of the cell are 
displayed.
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Immobilized proteoliposomes
MS
50 
 
  
51 
 
8
SUMMARY OF RESULTS
The work described in this thesis has aimed to increase the knowledge of membrane 
protein structure and function. Both directly by performing functional and structural 
studies of the human nociceptive ion channel TRPV1, and through development of 
methods that were validated using TRPV1 as a model membrane protein. The technique 
and associated methods can in principle be used to investigate any membrane protein.
Paper I describes a functional study of TRPV1 in which the importance of membrane 
cholesterol content for ion channel activity was evaluated. Paper II describes the 
development of a microfluidic flow cell used for both structural and functional studies of 
membrane proteins. Methods for performing such studies were developed in paper III and 
further extended for development of therapeutic antibodies in paper IV. 
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8.1 Paper I 
Membrane cholesterol content has been shown to be an important parameter for ion 
channel activity. TRPV1 has the capability to undergo a time dependent increase in 
permeability, a phenomenon called pore dilation. The dependence of membrane 
cholesterol content on this specific property was evaluated in paper I. The cholesterol 
content was lowered using cyclodextrins, and ion channel permeability was tested with 
patch clamp and fluorescence.   
During pore dilation, which occurs after prolonged activation in hypocalcemic conditions, 
TRPV1 is permeable to large cations such as N-methyl-D-glucamine (NMDG). This can 
be measured as an increase in relative permeability of NMDG compared to Na+ during 
whole cell patch-clamp experiments. This increase in permeability was found to be 
impaired in cells with lowered cholesterol content during activation with capsaicin, as the 
relative permeability was 70% lower in cholesterol depleted cells. 
TRPV1-mediated YO-PRO uptake was used to monitor pore dilation with laser scanning 
confocal microscopy. The effect of cholesterol content on pore dilation was evaluated 
using YO-PRO uptake with either capsaicin or protons as agonists. A 50% decrease in 
YO-PRO uptake was observed for cells having 36% less cholesterol during activation 
with capsaicin. This depletion was, however, not efficient enough to affect activation with 
protons although an effect on YO-PRO uptake during activation with protons was 
observed after 54% depletion.  
8.2 Paper II 
Paper II describes the development of the LPI microfluidic flow cell with the aim of 
performing proteomic characterization of membrane proteins.  Quartz crystal 
microbalance with dissipation monitoring (QCM-D) was used to characterize the amount 
of proteoliposomes binding to the flow cell surface. Proteoliposomes derived from red 
blood cells were used and bound within 5 min of injection until a total of 1 μg 
proteoliposomes/cm2 were found to cover the surface. The distribution of the 
proteoliposomes across the surface was even, as determined using atomic force 
microscopy. A hydrodynamic analysis was performed in order to determine if the forces 
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acting on the proteoliposomes during operation would be of an order that has the potential 
to cause rupture. The forces were evaluated to be in the range of 0.1–1 pN, which are 
tolerated by the proteoliposomes.
A sequential digestion protocol for limited proteolysis was developed to improve 
proteomic analysis of complex samples. The membrane proteins were subjected to a 
stepwise enzymatic digestion as well as single-step digestions. The digested peptides 
were then analyzed using liquid chromatography with tandem mass spectrometry (LC–
MS/MS). The mass spectrometer was able to detect 65% more unique membrane
proteins from samples originating from a sequential digestion as compared to a single-
step digestion. 
8.3 Paper III
In paper III, limited proteolysis was performed within the LPI flow cell developed in 
paper II, on the human TRPV1 ion channel, in order to gain structural information. 
Identical experimental conditions were also used during inside-out patch-clamp of 
TRPV1, where limited proteolysis was performed using the Dynaflow system for fast and 
controlled delivery of enzyme and agonist. The purpose of this study was to correlate the 
obtained structural data from using the LPI flow cell with functional information 
regarding different segments of TRPV1.
The functionality of TRPV1 located in proteoliposomes is a requirement for valid 
structural studies using the LPI flow cell. The activity of TRPV1 in its native state as well 
as after removal of different structural segments with tryptic digestion was measured 
using capsaicin-induced calcium release from proteoliposomes loaded with Ca2+. The 
fluorescent calcium-binding probe Fura-2 was used to confirm calcium release from 
proteoliposomes containing active ion channels. Both untreated proteoliposomes as well 
as proteoliposomes subjected to a short tryptic digestion exhibited active ion channels. 
Prolonged digestion however, diminished capsaicin response.
A screening of TRPV1 surface topology was performed using the sequential digestion 
protocol that was developed in paper II. Proteoliposomes containing hTRPV1 were 
derived from CHO cells and subjected to limited proteolysis with cumulative incubation 
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times within the LPI flow cell. An increasing number of peptides were detected with time, 
highlighting regions of the proteins that were accessible and easily digested, as well as
more rigid regions. Several of the regions that were observed as cleaved-off peptides after 
limited proteolysis of TRPV1 correlate with known interaction sites for calmodulin, ATP 
and PIP2.
The functionality of the digested regions was further evaluated using patch-clamp 
recordings and the  inside-out patch-clamp recording configuration, allowing the 
intracellular part of TRPV1 to be exposed to trypsin. A decrease in current response and 
single-channel conductance as well as an increase in EC50-values, could be observed with 
increasing trypsin concentrations. 
8.4 Paper IV
Paper IV describes the development and characterization of two polyclonal antibodies, 
OTV1 and OTV2, acting on the intracellular side of the human TRPV1 ion channel. Both 
antibodies are pharmacologically active, and their targeted epitope regions were chosen 
based on limited proteolysis of the target protein within the LPI microfluidic platform
using two different proteases. The efficacy of the antibodies against native TRPV1 was 
studied both with inside-out patch clamp, where the intracellular side of TRPV1 could be 
exposed to antibody solution, and with fluorescence studies where the antibodies were 
electroporated inside live cells. 
Immunocytochemistry was performed in order to visualize the antibody distribution 
within the cells. Cells were fixed and labeled with OTV1 or OTV2 followed by a
secondary goat anti-rabbit antibody tagged with Alexa 488. The fluorescence was 
visualized with confocal microscopy. Both OTV1 and OTV2 were found in the plasma 
membrane region.
For OTV1, current amplitudes were measured with the patch-clamp technique by 
exposing patches to capsaicin, with and without antibody. A ~50% decrease in current 
response were observed for cells treated with OTV1. For OTV2, current amplitudes were 
measured by exposing patches to capsaicin, with and without antibody and 
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calmodulin/Ca2+. A ~45% increase in current response (less desensitization) were 
observed for cells treated with OTV2.
The efficacies of the antibodies were also tested within whole cells using electroporation 
to permeabilize the cell membrane, followed by measurement of TRPV1 mediated YO-
PRO uptake with confocal microscopy. Cells were electroporated in the presence of either 
OTV1 or OTV2 and then exposed to YO-PRO and capsaicin. A 60% decrease in uptake 
rate could be observed during the initial 12 s of activation for OTV1 and an 80% increase 
in uptake rate could be observed at 15 s of activation for OTV2.
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CONCLUDING REMARKS
The method developments, and the study protocols, described herein will contribute to 
an improved understanding of how the lipid composition of the cell membrane as well as 
how structural manipulations of membrane proteins, and in particular ion channels,
modulate functional aspects of this protein class. In addition, the described methodologies 
will also facilitate the development of novel antibodies for therapeutic purposes.
The studies presented within this thesis have provided additional knowledge of TRPV1 
function and its role in pain reception. It has been previously known that the ion 
permeability of TRPV1 is not constant but increases with time. This phenomenon was 
shown to be dependent on membrane cholesterol levels, and was abolished by lowering 
the cholesterol content. A varying permeability can be an underlying mechanism through 
which TRPV1-mediated hyperalgesia occurs, and modulation of cholesterol content could 
in turn prove useful in pain treatment. Further studies are needed to support this finding in 
vivo and it would also be of interest to study the effect of increased cholesterol content on 
TRPV1 function as well as after modification of the content of other lipid species.
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This finding also highlights that many membrane proteins require a specific lipid 
composition for their correct function and that this is a parameter of great importance 
during structural and functional studies of membrane proteins. The LPI flow cell was 
developed to facilitate studies on immobilized membrane proteins still residing in their 
native membrane. It can be used with advantages for large-scale proteomic profiling as 
well as detailed studies of specific membrane proteins. The analysis can be limited to 
subcellular compartments by utilizing protocols for subcellular fractionation in order to 
select for a specific membrane type prior to the formation of proteoliposomes. 
The studies herein were performed using limited proteolysis as a tool for structure 
elucidation, but the use of the flow cell can be extended to any experimental procedure 
that would benefit from having membrane proteins in a stationary phase in non-
denaturing conditions. The environment surrounding the membrane proteins can easily be 
altered, e.g., to study the effect of different ionic compositions, pH or temperature. The 
protein of interest can be subjected to different ligands or other modulatory molecules in 
this context.  
The flow cell features a particularly large surface to volume ratio that allows for fast 
solution exchange during laminar flow conditions. The large surface area can bind a 
considerable amount of membrane material, which is beneficial due to the low abundance 
of certain membrane proteins. Fast solution exchange allows for a short digestion time, 
which is a prerequisite for limited proteolysis experiments. Peptides are preferably 
digested one at a time in order to rank regions based on their accessibility and surface 
exposure. This in turn requires precise control of protease activity and solution exchange. 
Detailed manipulation of membrane protein environment in combination with kinetically 
controlled proteolysis enabled evaluation of TRPV1 surface topology. Several flexible, 
surface exposed regions as well as regions resistant to proteolysis, were discovered using 
this approach. Inside-out membrane patches were subjected to limited trypsin proteolysis 
during patch-clamp recordings, causing removal of intracellular peptide regions and 
alterations in functional properties of TRPV1, such as its channel conductance. The 
identity of the digested regions could be confirmed with mass spectrometry after using 
identical digestion protocols within the LPI flow cell. The functional effect of shorter 
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segments could then be evaluated, which makes this technique more useful and less 
laborious in comparison to techniques for mutational studies.  Here, it is possible to study 
the effect of removal of single peptide segments on ion channel function by careful 
selection of protease concentration and digestion time. Proteases with different amino 
acid preferences could be combined in order to increase sequence coverage. 
Characterization of surface exposed peptide regions within the TRPV1 structure further 
facilitated the discovery of new epitopes for antibody generation. Two regions, one in the 
N-terminal and one in the C-terminal were both easily digested and located in known 
functionally important regions, thus chosen for antibody development. The antibody 
OTV1 binds to an epitope that is important for capsaicin activation of TRPV1 and 
subsequent capsaicin activation in the presence of OTV1 caused a decrease in current 
response. Similarly, the antibody OTV2 binds to an epitope that is important for 
desensitization with calmodulin and treatment with calmodulin in the presence of OTV2 
caused less desensitization. Thus, both antibodies caused a predicted alteration in TRPV1 
response based on the functional importance of their respective epitope region. This 
approach can be applied on membrane targets implicated in diseases for the development 
of new therapeutic antibodies. In cases where diseases are caused by mutated membrane 
proteins, cell lines expressing these dysfunctional proteins can be used for limited 
proteolysis and epitope generation. Epitopes generated from such experiments could 
potentially produce antibodies able to select between functional and dysfunctional 
proteins. 
The established techniques mass spectrometry and patch clamp constitute valuable 
methodologies for studies of structural and functional aspects of membrane proteins, such 
as ion channels. These methods were used in conjunction with newly developed 
techniques which further enables detailed and advanced studies of structure-to-function 
relationships of this group of membrane proteins. Finally, this combination of novel and 
established methodologies may also constitute an effective strategy for generating 
antibodies with therapeutic properties. 
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